Stock research
NAMS NewAmsterdam Pharma Company N.V.
Healthcare • Biotechnology
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose...…
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
1Y change
+27.15%
Range high
$41.45
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in NAMS?
Price
Showing 1Y history. Source: FMP historical price full.
- Prev Close
- $27.55
- Day High
- $27.85
- Day Low
- $25.74
- 52w High
- $42.21
- 52w Low
- $21.23
- Volume
- 1,152,978.09746
- Avg Volume
- Beta
- 0.11
* TTM/most recent where available
Company
- Ticker
- NAMS
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- NL
- CEO
- Michael Davidson
- Employees
- 100
- Website
- www.newamsterdampharma.com
Key Metrics
- Market Cap
- 3.22B
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).